Scinai Immunotherapeutics Ltd. (SCNI) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Jerusalem, イスラエル. 現CEOは Amir Reichman.
SCNI を有する IPO日 2015-05-11, 31 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $802.37K.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
